Global private equity and venture capital news and research

Healthcare & Life Sciences

10 February 2015

Weak start to the year for global biotech investment valuep

biotech virus lab The value of private equity, venture capital and development capital investment in the global biotechnology sector decreased in January compared to the previous month despite a rise in volume. A total of $455m was invested in biotech companies over the four weeks, down 82 per cent from a high base of $2.58bn in December according to[...]

17 February 2014

Mega buyout boosts biotech private equity activityp

The value of private equity, venture capital and development capital investment targeting biotechnology companies started 2014 on an impressive note, leaping to its highest point in the last 12 months.

17 September 2013

Fundraising for life science VCs continues decline in 2013p

Fundraising by life science venture capitalists continued to decline during 2013, with estimated fundraising for the first half of the year falling to $1.3bn, corresponding to an annualized rate of $2.6bn.

22 August 2013

Momentum builds in healthcare venture capitalp

Large exits, specifically those venture capital-backed healthcare deals with at least $75m upfront in biotech and $50m upfront for medical device and services hit an eight-year high, according to a recent report.

3 April 2013

Media & technology M&A sees month-on-month boostp

A total of 336 M&A deals were announced in the media and technology space in March 2013, as strategic buyers and venture capital and growth investors stepped up their activity.

25 February 2013

US life sciences sees double digit dip in VC activityp

US venture capital funding in the life sciences sector dropped 14 per cent in dollars and seven per cent in deals during 2012, new research has found.

18 January 2013

Private equity leads push for healthcare, pharma IT dealsp

Private equity firms were responsible for four of the top ten deals in the global pharma/ healthcare IT industry, as transaction volumes increased 21 per cent and deal values also increased.

16 January 2013

Private equity could profit from big pharma divestituresp

As big pharma companies look to sharpen their strategic focus, it is likely they will consider more divestures of non-strategic assets – with corporate investors and private equity seen as likely acquirers.

20 July 2012

Double-digit increase for VC dollars, dealsp

US venture capitalists invested $7bn in 898 deals in the second quarter of 2012. Quarterly venture investment activity climbed 17 per cent in terms of dollars and 11 per cent in the number of deals.

12 February 2010

The European life sciences market – things can only get better…can’t they?p

It could be said that 2009 has been a challenging year for the industry, particularly for the early stage companies. We have seen low levels of investment into the life sciences sector, several companies going out of business or having to make fire sales, and the IPO window being firmly shut. As predicted in our 2009 report, the venture capital and private equity houses have tended to stay very close to their portfolio companies and have invested little of their money into new ventures. The year was not devoid of success stories, however, with some of the larger public companies performing well, and the doomsday scenario of the total drying up of debt not as bad as many feared, thanks in some part to various government interventions. But, on the whole, people will not look back on 2009 with happy memories.

Page 1 of 1612345...10...Last »

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2015